09:54 AM EST - Protox Therapeutics Inc. : announced the positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302, TRIUMPH in patients with moderate to severe benign prostatic hyperplasia or BPH, a painful and bothersome urological condition that affects more than 50 million men worldwide. The company noted that the study achieved its primary clinical endpoint of a statistically significant improvement in International Prostate Symptom Score or IPSS for patients treated with PRX302 versus subjects receiving placebo. Protox Therapeutics Inc.
shares T.PRX are trading up $0.08 at $0.97.
